KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.
Price Chart
Executive Summary
BTIG initiated coverage on KMTS with a Buy rating and $32 price target, the highest among seven analysts, implying 59% upside from the current $20.05. Consensus target is $28.71 with median at $30; KMTS trades below all but Goldman Sachs’ $17 PT. BTIG has a 53% accuracy rate (503/948) and average return of 3.7%, slightly below top-tier firms. No upgrades or downgrades in past 30 days, but EPS estimates show minor upward revisions over 7-day horizon. Goldman Sachs, Wells Fargo, and Piper Sandler maintain Overweight/Neutral ratings with mixed track records—Goldman at 0% accuracy (0/3), Wells at 33% (1/3), Piper at 0% (0/2). Insider activity is split: $200K buy by COHEN RAYMOND W vs $304K sell by Webster Brian Daniel. No congressional trades or institutional changes reported. Earnings date not disclosed; no imminent catalyst flagged.
Impact Score
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-09 | Goldman Sachs | maintain | Neutral | $17.00 |
| 2026-04-07 | BTIG | reiterate | Buy | $32.00 |
| 2026-03-25 | BTIG | reiterate | Buy | — |
| 2026-03-18 | BTIG | reiterate | Buy | — |
| 2025-12-15 | Goldman Sachs | maintain | Neutral | $25.00 |
| 2025-12-12 | Wells Fargo | maintain | Overweight | $28.00 |
| 2025-12-12 | Piper Sandler | maintain | Overweight | $30.00 |
| 2025-11-18 | BTIG | initiate | Buy | $32.00 |
| 2025-07-17 | Wells Fargo | maintain | Overweight | $27.00 |
| 2025-04-16 | Goldman Sachs | maintain | Neutral | $23.00 |
No analyst upgrades or downgrades in the past 30 days. EPS revisions show minimal movement: 1 upward revision each in 7-day and 30-day windows, no downward revisions in past 7 days, but 1 down revision in past 30 days across all periods. Estimates remain stable: current 0Y EPS at -2.33, down from -2.315 30 days ago, indicating slight deterioration despite recent upward tweaks.
Firm Track Record — BTIG
BTIG accuracy: 53% on 948 calls | avg return: 3.7%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 3 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Wells Fargo | 33% | 1/3 | -4.8% | below average |
| Goldman Sachs | 0% | 0/3 | -34% | below average |
| Piper Sandler | 0% | 0/2 | -31.9% | below average |
BTIG has a 53% accuracy rate (503 correct out of 948 rated stocks) with an average return of 3.7%, placing it slightly below the top-performing firms. Among peers covering KMTS, Wells Fargo has 33% accuracy (1/3), Goldman Sachs 0% (0/3), and Piper Sandler 0% (0/2)—all below average. BTIG is the most credible firm on record, though not elite.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $-2.33 | $-2.36 — $-2.30 | $93.0M | ↑1 ↓0 |
| +1q | $-0.54 | $-0.55 — $-0.53 | $28.0M | ↑1 ↓0 |
| +1y | $-2.14 | $-2.37 — $-1.91 | $132.9M | ↑1 ↓0 |
| 0q | $-0.58 | $-0.61 — $-0.55 | $26.5M | ↑1 ↓0 |
Cross-Platform Signals
Insider activity is mixed: $199.8K buy by COHEN RAYMOND W on 2026-03-26 contrasts with $304.1K sell by Webster Brian Daniel on 2026-03-17. No congressional trades, institutional position changes, or short interest data available. Insider signal diverges from analyst sentiment—executive selling offsets minor buying, weakening confirmation of bullish thesis.
Actionable Insight
BTIG’s initiation offers a high-conviction bullish entry point with strong upside potential, supported by the highest price target and relatively better firm accuracy. Favorable EPS revision trends and majority Buy consensus justify long positioning, but lack of earnings catalyst and mixed insider signals warrant cautious entry.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 16, 2026
27d ago
|
ANALYST-UPGRADE
| $25.65 $26.82 | ▲ +4.56% | ▲ +2.26% | $20.85 (−18.71%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $20.41 $21.45 | ▲ +5.10% | ▼ −0.72% | $20.85 (+2.16%) |
|
Apr 1, 2026
10w ago
|
S-3ASR
| $19.84 $20.72 | ▲ +4.44% | ▼ −5.44% | $20.85 (+5.09%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $19.58 $20.41 | ▲ +4.24% | ▼ −1.81% | $20.85 (+6.49%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $22.92 $19.93 | ▼ −13.05% | ▼ −8.64% | $20.85 (−9.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access